TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02526472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ET under transabdominal US guidance (UGET)
Description: When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ET after transvaginal US uterine measurement (mTVET)
Description: When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
Study: NCT01863212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for genetic analyse
Description: Blood sampling are performed at the initiation visit in order to screen for allele variants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for genetic analyse
Description: Blood sampling are performed at the initiation visit in order to screen for allele variants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroop test
Description: Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroop test
Description: Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging, performed to view brain activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging, performed to view brain activity
Study: NCT02504008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-02 (oral zoledronate)
Description: Once weekly for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once weekly for 6 weeks
Study: NCT03701347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reeve's model
Description: Reeves, K. O., Young, A. E., \& Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hefler's model
Description: Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., \& Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ida's model
Description: Reusable, portable and modular 3D printed simulator
Study: NCT03543904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-operative physiotherapy intervention
Description: Post-operative physiotherapy intervention which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises
Study: NCT03176056

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calori restricted diet
Description: For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI \> 24 and 30 kcal/day for underweight subjects with a BMI \<18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
Study: NCT03132779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Adose of intralipid given and rechecking NKcells activity
Study: NCT01693575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupil expansion with APX 100 device
Description: Patients with small pupils (\<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
Study: NCT01881776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB
Description: In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter.
Study: NCT03006458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon B
Description: toric contact lens
Study: NCT03011970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04442126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM21-1480
Description: Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein
Study: NCT03315273

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test battery to measure the motor imagery ability
Description: Participants will perform 3 different tests to measure the motor imagery ability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test battery to measure the motor imagery ability
Description: Participants will perform 3 different tests to measure the motor imagery ability
Study: NCT00597311

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv
Study: NCT00530829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc
Description: 10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc
Description: 10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
Study: NCT00998751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral masitinib
Description: 7.5 mg/kg/day
Study: NCT03985410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral tablet
Study: NCT02373956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MELECTIS G
Description: The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MELECTIS G
Description: The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
Study: NCT00634712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00050531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-alpha interferon (Peg-Intron)
Description: PEG-IFN 0.5 mcg/kg each week subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-alpha interferon (Peg-Intron)
Description: PEG-IFN 0.5 mcg/kg each week subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: 125 mcg/m\^2 three times per week subcutaneously.
Study: NCT01844102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex
Description: PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
Study: NCT03484481

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Nutritional Support; Nutrena
Description: Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Nutritional Support; Nutrena
Description: Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Intradialytic Parenteral Nutrition; Kabiven central
Description: Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
Study: NCT00005610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT02356055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOMP (Skill-building through Task-Oriented Motor Practice)
Description: The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STOMP (Skill-building through Task-Oriented Motor Practice)
Description: The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
Study: NCT02193932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG Triggered fMRI using Micro Maglink
Study: NCT00861003

Intervention type: DEVICE
Intervention: Medication Event Monitoring System (MEMS)
Description: MEMS is a medication vial cap that electronically records the date and time of bottle opening.
Study: NCT02506452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biovance®
Description: Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Diabetic Foot Ulcers
Description: Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Diabetic Foot Ulcers
Description: Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
Study: NCT03690557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IncentaHealth
Description: IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
Study: NCT02397707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: 100 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: 100 mg tablet administered orally
Study: NCT02157948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab (CP2)
Description: Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (CP4)
Description: Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
Study: NCT01276275

Intervention type: DRUG
Intervention: Risk of selected safety events
Description: First time users of ticagrelor, clopidogrel and prasugrel, respectively

Intervention type: DRUG
Intervention: Risk of selected safety events
Description: First time users of ticagrelor, clopidogrel and prasugrel, respectively

Intervention type: DRUG
Intervention: Risk of selected safety events
Description: First time users of ticagrelor, clopidogrel and prasugrel, respectively
Study: NCT04230941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAT-G
Description: Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
Study: NCT02736422

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarised Xenon
Description: Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
Study: NCT01077700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288 Low Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288 High Dose
Study: NCT03041155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle respiratory training
Description: Muscle respiratory training during hemodialysis sessions
Study: NCT04597866

Intervention type: BEHAVIORAL
Intervention: Multimodal rehabilitation
Description: A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
Study: NCT00390884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Fluzone®
Description: 0.25 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Fluzone®
Description: 0.25 mL, Intramuscular
Study: NCT04477707

Intervention type: DRUG
Intervention: Finerenone (BAY94-8862)
Description: 10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
Study: NCT03104530

Intervention type: OTHER
Intervention: Brown crabmeat
Description: Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
Study: NCT02227134

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
Study: NCT03593707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin
Study: NCT03593707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: PF-06865571
Study: NCT00539331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: oral tablet
Study: NCT03670121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Thermal Vapor Ablation (BTVA)
Description: Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
Study: NCT03088800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Oral Ibuprofen at 10 mg/kg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Oral Ibuprofen at 10 mg/kg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: Oral APAP at 15mg/kg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: Oral APAP at 15mg/kg dose
Study: NCT04724265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collection of sample of perilymphatic fluid during cochlear implantation
Description: collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
Study: NCT00539331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injection